Form 4: Elevation Oncology Director Granted 35,000 Stock Options

Darcy Mootz, a Director at Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options with an exercise price of $0.3051 per share, vesting over one year.

Summary

• Darcy Mootz, a Director of Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options on June 5, 2025.
• The exercise price for these options is $0.3051 per share.
• The options are scheduled to vest 100% on the one-year anniversary of the grant date, subject to Darcy Mootz's continued service to the Issuer.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Darcy Mootz beneficially owns 35,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders and incentivizes long-term commitment, which is generally viewed favorably.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

The vesting schedule of the stock options indicates an expectation of continued service from Darcy Mootz to Elevation Oncology for at least one year from the grant date.

Industry Context

The granting of stock options is a common form of equity compensation for directors and executives in the biotechnology and pharmaceutical industries, aiming to incentivize performance and align leadership interests with long-term shareholder value.

Related Party Transactions

• The transaction involves the grant of stock options from Elevation Oncology, Inc. to Darcy Mootz, a Director of the company, which is a related party transaction.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align their interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting all employees, such compensation practices can set precedents for executive and director incentives within the company.

Next Steps

• The stock options will vest on the one-year anniversary of the grant date (June 5, 2026), provided the reporting person continues to provide service to the Issuer.

Key Dates

Keywords

Elevation Oncology, ELEV, SEC Form 4, Stock Option Grant, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership